Lipid-based nano delivery of Tat-peptide conjugated drug or vaccine-promising therapeutic strategy for SARS-CoV-2 treatment

Mohammad Azam Ansari; Ahmad Almatroudi; Mohammad A Alzohairy; Sami AlYahya; Mohammad N Alomary; Hanan A Al-Dossary; Saad Alghamdi

doi:10.1080/17425247.2020.1813712

Lipid-based nano delivery of Tat-peptide conjugated drug or vaccine-promising therapeutic strategy for SARS-CoV-2 treatment

Expert Opin Drug Deliv. 2020 Dec;17(12):1671-1674. doi: 10.1080/17425247.2020.1813712. Epub 2020 Aug 31.

Authors

Mohammad Azam Ansari¹, Ahmad Almatroudi², Mohammad A Alzohairy², Sami AlYahya³, Mohammad N Alomary⁴, Hanan A Al-Dossary¹, Saad Alghamdi⁵

Affiliations

¹ Department of Epidemic Disease Research, Institute for Research & Medical Consultations (IRMC), Imam Abdulrahman Bin Faisal University , Dammam, Saudi Arabia.
² Department of Medical Laboratories, College of Applied Medical Sciences, Qassim University , Qassim, Saudi Arabia.
³ National Center for Biotechnology, King Abdulaziz City for Science and Technology , Riyadh, Saudi Arabia.
⁴ National Center for Biotechnology, Life Science and Environmental Research Institute, King Abdulaziz City for Science and Technology , Riyadh, Saudi Arabia.
⁵ Laboratory Medicine Department, Faculty of Applied Medical Sciences, Umm Al-Qura University , Makkah, Saudi Arabia.

No abstract available

Keywords: COVID-19; Sars-CoV-2; Tat-peptide; drug delivery; lipid-based nanocarriers; outbreak; Nanoformulations; pandemic; silver bullet; vaccine.

Publication types

Editorial

Grants and funding

This paper was funded by the Deanship of Scientific Research, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia [Grant number-Covid19-2020-002-IRMC].